OTTAWA, ONTARIO--(Marketwired - Oct. 28, 2014) - Canadian company AvidBiologics Inc. and the National Research Council of Canada (NRC) are collaborating on one of the most promising advances in the fight against cancer: antibody-drug conjugates (ADCs). Recently signed research and licensing agreements will enable both organizations to continue developing a series of ADCs targeting breast, lung, and head-and-neck cancers. Unlike chemotherapy, ADCs specifically seek and destroy cancer cells, with minimal impact on healthy cells.
Since the start of the project in early 2013, NRC's antibody expertise has helped advance AvidBiologics' lead treatment more rapidly. By late September 2014, the data helped convince Avid's investors to close a new financing round. Avid will now complete confirmatory preclinical testing for its lead candidate in anticipation of its initial clinical trial in 2015, bringing this promising new treatment several steps closer to patients.
The National Research Council of Canada also developed a custom cell line needed to produce the antibody and is optimizing the parameters for its production. The goal is to transfer the cell line and bioprocess to a Canadian contract manufacturing organization to produce the clinical trial material.
- In Canada, about 157,000 people are currently diagnosed with breast cancer, 39,500 with lung cancer, and 5,000 with head-and-neck cancers.
- Antibody-drug conjugates combine the targeting attributes of antibodies with the cancer-destroying properties of drugs that are toxic to cells.
- Toronto-based AvidBiologics is a leading Canadian biotech company that focuses solely on antibody-drug conjugates.
- NRC's research and development of new cancer treatments is aligned with the Government of Canada's commitment to ensuring the health of Canadians. The collaboration with Avid exemplifies how NRC is helping industry progress research from the lab to the marketplace.
"Our work with leading Canadian biotech companies such as AvidBiologics shows how the National Research Council's world-class expertise can help in the fight against cancer and improve the lives of Canadians."
Roman Szumski, Vice-President of Life Sciences at the National Research Council of Canada
"The work performed by NRC is crucial to assembling the data package needed for clinical trials. We are privileged to be able to continue the rapid development of our lead candidate while advancing the other candidates in the pipeline in collaboration with the NRC. We thank the NRC and all of our partners for their support as AvidBiologics transitions from a discovery-stage to a development-stage company."
Ilia A. Tikhomirov, President and CEO of Avid Biologics
AvidBiologics financing news release
AvidBiologics collaboration with NRC news release
NRC Biologics research program